MARKET

RLMD

RLMD

Relmada Therapeutics Inc
NASDAQ
2.620
-0.490
-15.76%
After Hours: 2.620 0 0.00% 19:30 11/20 EST
OPEN
3.070
PREV CLOSE
3.110
HIGH
3.130
LOW
2.603
VOLUME
2.25M
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
2.603
MARKET CAP
278.47M
P/E (TTM)
-3.3316
1D
5D
1M
3M
1Y
5Y
1D
Relmada Therapeutics, Inc. Appoints Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
NASDAQ · 4d ago
Leerink Partners Keeps Their Buy Rating on Relmada Therapeutics (RLMD)
TipRanks · 4d ago
Relmada Therapeutics Appoints Chief Development Officer for Urology
TipRanks · 4d ago
Weekly Report: what happened at RLMD last week (1109-1113)?
Weekly Report · 4d ago
Press Release: Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Dow Jones · 4d ago
Relmada Therapeutics (RLMD) Gets a Buy from H.C. Wainwright
TipRanks · 11/13 14:39
Piper Sandler Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)
TipRanks · 11/13 14:05
Relmada Therapeutics Reports Third-Quarter Results and Business Update
TipRanks · 11/12 21:43
More
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Webull offers Relmada Therapeutics Inc stock information, including NASDAQ: RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.